Anti-BCMA novel therapies for multiple myeloma

Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sammartano, Vincenzo, Franceschini, Marta, Fredducci, Sara, Caroni, Federico, Ciofini, Sara, Pacelli, Paola, Bocchia, Monica, Gozzetti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099603/
https://www.ncbi.nlm.nih.gov/pubmed/37065871
http://dx.doi.org/10.20517/cdr.2022.138
_version_ 1785025088606699520
author Sammartano, Vincenzo
Franceschini, Marta
Fredducci, Sara
Caroni, Federico
Ciofini, Sara
Pacelli, Paola
Bocchia, Monica
Gozzetti, Alessandro
author_facet Sammartano, Vincenzo
Franceschini, Marta
Fredducci, Sara
Caroni, Federico
Ciofini, Sara
Pacelli, Paola
Bocchia, Monica
Gozzetti, Alessandro
author_sort Sammartano, Vincenzo
collection PubMed
description Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.
format Online
Article
Text
id pubmed-10099603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-100996032023-04-14 Anti-BCMA novel therapies for multiple myeloma Sammartano, Vincenzo Franceschini, Marta Fredducci, Sara Caroni, Federico Ciofini, Sara Pacelli, Paola Bocchia, Monica Gozzetti, Alessandro Cancer Drug Resist Review Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents. OAE Publishing Inc. 2023-03-22 /pmc/articles/PMC10099603/ /pubmed/37065871 http://dx.doi.org/10.20517/cdr.2022.138 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Sammartano, Vincenzo
Franceschini, Marta
Fredducci, Sara
Caroni, Federico
Ciofini, Sara
Pacelli, Paola
Bocchia, Monica
Gozzetti, Alessandro
Anti-BCMA novel therapies for multiple myeloma
title Anti-BCMA novel therapies for multiple myeloma
title_full Anti-BCMA novel therapies for multiple myeloma
title_fullStr Anti-BCMA novel therapies for multiple myeloma
title_full_unstemmed Anti-BCMA novel therapies for multiple myeloma
title_short Anti-BCMA novel therapies for multiple myeloma
title_sort anti-bcma novel therapies for multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099603/
https://www.ncbi.nlm.nih.gov/pubmed/37065871
http://dx.doi.org/10.20517/cdr.2022.138
work_keys_str_mv AT sammartanovincenzo antibcmanoveltherapiesformultiplemyeloma
AT franceschinimarta antibcmanoveltherapiesformultiplemyeloma
AT fredduccisara antibcmanoveltherapiesformultiplemyeloma
AT caronifederico antibcmanoveltherapiesformultiplemyeloma
AT ciofinisara antibcmanoveltherapiesformultiplemyeloma
AT pacellipaola antibcmanoveltherapiesformultiplemyeloma
AT bocchiamonica antibcmanoveltherapiesformultiplemyeloma
AT gozzettialessandro antibcmanoveltherapiesformultiplemyeloma

Ejemplares similares